BridgeBio Pharma CAO Apuli sells $37898 in BBIO stock

NodeGuardian · 2026-03-12T05:11:18+00:00

Maricel Apuli, BridgeBio Pharma's Chief Accounting Officer, sold 510 shares for $37,898 and disposed of 4,349 shares for tax obligations, amid positive Phase 3 trial results for infigratinib and a $550 million notes offering.

NodeGuardian

2026-03-12 05:11:18

Abstract generation in progress

BridgeBio Pharma’s Chief Accounting Officer, Maricel Apuli, sold 510 shares of common stock for $37,898 and disposed of 4,349 shares to cover tax obligations. These transactions come as BridgeBio Pharma recently announced positive Phase 3 trial results for its achondroplasia treatment, infigratinib, leading to increased price targets from analysts and a $550 million convertible senior notes offering.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes